Despite a substantial improvement in net profit margin and a lower future P/E ratio, reflecting enhanced profitability and potentially more attractive valuation, the consensus Analyst Price Target for Oncopeptides has been revised downward from SEK2.99 to SEK2.73.
What's in the News
- Two real-world evidence posters on Pepaxti for relapsed/refractory multiple myeloma accepted for presentation at the International Myeloma Society Annual Meeting, highlighting growing clinical use and importance of real-world data.
- Sales guidance for Q2 2025 raised, with expected net sales of SEK 19.2 million versus SEK 8.2 million in Q2 2024; six-month sales expected at SEK 32.5 million versus SEK 13.2 million in the prior year period.
- Pepaxti included in new EHA-EMN clinical guidelines for relapsed/refractory multiple myeloma, receiving Level 1 evidence and Grade B recommendation for triple-class refractory/exposed patients, including post-immunotherapy settings.
- First patient enrolled in Spanish real-world evidence study (LAGOON) for Pepaxti in RRMM; complements earlier similar study (HARBOUR) in Germany, aiming to bolster clinical and market insights across Europe.
- Ordinary shares to be delisted from OTC Equity effective May 6, 2025, due to inactive security.
Valuation Changes
Summary of Valuation Changes for Oncopeptides
- The Consensus Analyst Price Target has fallen from SEK2.99 to SEK2.73.
- The Future P/E for Oncopeptides has significantly fallen from 12.02x to 8.87x.
- The Net Profit Margin for Oncopeptides has significantly risen from 18.66% to 21.33%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.